ACLS vs LRCX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACLS and LRCX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACLS and LRCX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Ion implantation is the process step that shoots charged atoms into silicon wafers to change their electrical properties, and it is essential to making almost every chip. The company's Purion product family serves a wide range of end markets, including power devices (notably silicon carbide chips used in electric vehicles and industrial systems), image sensors, general mature-node logic, and memory such as DRAM and high-bandwidth memory (HBM). Ion implantation makes up the large majority of revenue, so Axcelis is a fairly pure play on that one process step rather than a diversified equipment giant.

Full ACLS guide

Lam Research is one of the largest semiconductor equipment makers in the world, specializing in wafer-fabrication tools used to build integrated circuits. It is a leader in two critical process steps: etch (precisely removing material to carve nanoscale features) and deposition (laying down ultra-thin films of material), along with related cleaning and surface-preparation systems. These steps are repeated hundreds of times to build modern 3D chip structures, and Lam's tools are essential to manufacturing advanced logic and especially memory chips (DRAM and NAND flash). Lam sells its systems to the world's leading chipmakers and foundries, then earns a large, recurring stream of revenue from spare parts, upgrades, and services for its big installed base of tools, which smooths the cyclical equipment-sales business. Demand is driven by capital spending from semiconductor manufacturers, which rises and falls with chip-industry cycles but trends structurally higher as AI, data centers, and advanced devices require more and more sophisticated chips. Headquartered in Fremont, California, Lam is a key enabler of leading-edge and memory chip production.

Full LRCX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ACLS drivers: Memory recovery (DRAM and HBM); Power devices and silicon carbide.
• LRCX drivers: AI-driven chip-capex supercycle; Leadership in etch and deposition.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. For LRCX, semiconductor equipment is highly cyclical, and Lam's new-tool sales swing sharply with chipmaker capital-spending cycles, especially in memory, which is among the most volatile end markets.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ACLS if you believe its drivers more; LRCX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACLS and LRCX guides.

ACLS. Axcelis revenue fell from about $1.02 billion in 2024 to roughly $839 million in 2025 as power and silicon carbide demand cooled, and net income compressed to around $120 million. With earnings down and the stock near $140, the trailing P/E of roughly 43x is elevated versus the company's own history, reflecting expectations for a memory-led recovery and the pending Veeco merger. All figures are approximate and change with each quarter and the market.

LRCX. Lam trades at a multiple reflecting both strong secular demand for chip equipment and the cyclicality of the memory-heavy equipment market. The valuation embeds expectations of a structural rise in semiconductor capital spending driven by AI, balanced against export-control risk and the swing factor of memory capex. The large, higher-margin installed-base service revenue supports a premium over a purely cyclical equipment maker. Lam also returns substantial cash through buybacks and a growing dividend.

Headline figures (approximate, JULY 2026): ACLS shows revenue (fy2025) ~$839 million, net income (fy2025) ~$120 million, revenue (ttm) ~$845 million, q1 2026 revenue ~$199 million (GAAP EPS ~$0.30); LRCX shows revenue (ttm) ~$16 billion, operating margin ~30%, net income (ttm) ~$4-5 billion, p/e (ttm) ~25x.

ACLS and LRCX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ACLS and LRCX exposure against your real portfolio. It is not an investment adviser.